Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    men's health

    Prostate cancer

    Also known as: Prostatic carcinoma, Carcinoma of the prostate, Prostatic adenocarcinoma

    Prostate cancer is a malignancy requiring specialist urological and oncological management, involving risk stratification, surveillance, or appropriate treatment. Adjunctive Chinese medicine must be oriented toward mitigating treatment-induced sequelae rather than primary tumour control. Current literature includes a review protocol with no reported outcomes [1], in vitro/in vivo research on luteolin without established clinical utility [2], and a narrative review regarding post-prostatectomy urinary incontinence limited by evidence constraints [3]. A small exploratory analysis (n=35) indicated potential improvements in nocturia compared to waitlist controls, though findings require validation [4]. These records do not demonstrate survival benefits or therapeutic efficacy for the listed formulas. Safety guidance is provided as a clinical safeguard and remains untested within these abstracts; all adjunctive care must be coordinated with the patient's oncology team.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Maintain a three-day bladder diary documenting voiding frequency, volumes, episodes of incontinence, and nocturia for clinical evaluation.
    • •Consult the medical team regarding the timing of evening caffeine, ethanol, and fluid intake; avoid dehydration and ensure any fluid restriction is medically supervised.
    • •Adhere to a tolerable physical activity regimen, ensuring professional guidance accounts for fatigue levels, post-surgical recovery, and the status of bone metastases.
    • •Prioritise regular nutritional and sleep hygiene; seek dietetic or psychological intervention if appetite, weight, or psychological coping mechanisms deteriorate.

    Cautions & Contraindications

    See sources
    • •Do not replace active surveillance, surgery, radiotherapy, systemic therapy or scheduled PSA monitoring with acupuncture, herbs or supplements. The supplied integrative-care paper is a protocol without outcome results.[]
    • •Defer needling during fever or suspected infection and obtain oncology clearance when neutropenia, thrombocytopenia, bleeding tendency or anticoagulation raises procedural risk. These are clinical precautions, not thresholds established by the supplied protocol.[]
    • •Do not needle through tumour deposits, infected or broken skin, unhealed surgical sites or acute radiation injury. Avoid compromised lymphatic drainage areas unless specialist clearance is obtained; the supplied abstracts do not test these precautions.[]
    • •Do not initiate formulas without oncology medication reconciliation and a product-quality check. The protocol plans to assess herb–drug interactions but provides no completed safety findings.[]
    • •Do not recommend concentrated luteolin supplements as an anticancer intervention on the basis of stem-cell mechanisms; the supplied study does not establish clinical benefit, a safe regimen or compatibility with cancer medicines.[]

    When to reassess or seek care again

    See sources

    Agree baseline goals and review after 2–4 weeks: nocturia episodes from a three-day diary, pads used per day, sleep disruption and 0–10 fatigue or distress scores. Record adverse effects and treatment changes. Stop or revise adjunctive care if there is no meaningful agreed improvement, and refer worsening urinary symptoms, new pain, weight loss or deteriorating function promptly. Red flags require immediate escalation; PSA and disease-response monitoring remain with oncology.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. JMIR research protocols · 2026
    2. Molecular and cellular biochemistry · 2026
    3. Zhonghua nan ke xue = National journal of andrology · 2026
    4. JU open plus · 2026

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.